Aktis Oncology

IPO

Aktis Oncology is a healthcare company in Boston, United States, founded in 2020. It has raised $430.0M across 3 rounds, most recently a $175.0M Series B in September 2024.

Next-generation precision radiopharmaceuticals

Employees
51–200
Founded
2020
Business Model
B2B
Total Funding
$430.0M
Last Round
$175.0M Series BSep 2024
Rounds
3
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 9 investors for this company. The full record is or through the API.

About

Aktis Oncology is a biotechnology company pioneering a new class of targeted radiopharmaceuticals for the treatment of cancer patients with significant unmet needs. Founded in 2020 and backed by MPM Capital, the company has built a proprietary miniprotein radioconjugate platform that delivers targeted alpha-particle radiation to tumor cells with the goal of breakthrough efficacy across broad patient populations. Their pipeline addresses prevalent tumor types historically beyond the reach of radiopharmaceuticals. Aktis raised a $175 million Series B in October 2024 and completed an upsized IPO on Nasdaq (AKTS) in January 2026, becoming the first biotech IPO of that year.

Summary

It lists 51–200 employees. It has raised $430.0M in total across 3 rounds, most recently a $175.0M Series B round in Sep 2024. Investors include MPM Capital, Vida Ventures and EcoR1 Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
IPO2026 (est.)
$318.0M

Sign up to see all 4 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

MultiPlanIPO

Healthcare cost management company providing data analytics and network-based payment solutions t...

New York, United States1001–5000Healthcare
Private EquityTotal funding$7.4BMar 2014
The Bountiful CompanyAcquired

American dietary supplements company owning Nature's Bounty, Solgar, and Puritan's Pride brands; ...

Ronkonkoma, United States1001–5000Healthcare, Retail
Private EquityTotal funding$7.0BJul 2017
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
OneOncologyAcquired

OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...

Nashville, United States1001–5000Healthcare, Data & Analytics
Extension RoundTotal funding$5.1BDec 2025
Canopy Growth Corporation Common SharesIPO

World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...

Smiths Falls, Canada1001–5000Healthcare
Corporate RoundTotal funding$4.5BJan 2024
Inizio

Inizio helps health and life sciences clients realize product potential through deep expertise, g...

New York, United States10001+Healthcare
Venture RoundTotal funding$4.4B

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Aktis Oncology on Indexed.vc
<a href="https://indexed.vc/companies/aktis-oncology"><img src="https://indexed.vc/api/badge/company/aktis-oncology" alt="Aktis Oncology on Indexed.vc" width="260" height="76" /></a>